MENU
INKT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
MiNK Therapeutics (INKT) Earnings Date & Reports
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more
A.I. Advisor
published Earnings
INKT is expected to report earnings to rise 6.45% to -66 cents per share on March 23
Q4'26
Est.
$-0.66
Q2'26
Beat
by $0.25
Q1'26
Missed
by $0.39
Q4'25
Missed
by $0.44
Q3'25
Missed
by $0.58
The last earnings report on August 13 showed earnings per share of -62 cents, beating the estimate of -87 cents. With 10.37K shares outstanding, the current market capitalization sits at 51.80M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Related Blogs
Interesting Articles
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Industry
N/A
Address
149 Fifth Avenue
Phone
+1 212 994-8250
Employees
15
Web
https://www.minktherapeutics.com